Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Duchenne Muscular Dystrophy
Conditions
Duchenne Muscular Dystrophy
Trial Timeline
Oct 31, 2020 → May 13, 2021
NCT ID
NCT04708314About Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]
Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] is a approved stage product being developed by Sarepta Therapeutics for Duchenne Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT04708314. Target conditions include Duchenne Muscular Dystrophy.
What happened to similar drugs?
1 of 19 similar drugs in Duchenne Muscular Dystrophy were approved
Approved (1) Terminated (7) Active (11)
Hype Score Breakdown
Clinical
20
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04708314 | Approved | Terminated |
Competing Products
20 competing products in Duchenne Muscular Dystrophy